STG Media Corp. Launches Sinol Nasal Sprays, The First Over-The-Counter Nasal Sprays For Headache, Allergy And Sinus Relief

STG Media Corp. has launched SINOL for Allergy and Sinus and SINOL for Headache into mass-market. Expected to be a top seller, SINOL will hit the shelves of 15,000 mass-market retailers in May. “The Sinol Brand has been fun and challenging,” said Thomas Lark CEO of STG Media Corp. “We went through an evolution of repackaging, focus groups, and re-positioning. Ultimately we formed two different SKU’s, one for sinus headache relief and one for allergy treatment. Diversifying the product’s retail positioning in both analgesic and allergy really made the difference, especially when coupled with the targeted national TV, magazine and radio campaign designed to drive consumers to retail, while simultaneously accruing direct response revenue.” Sinol® Headache Nasal Spray is the first FDA approved all natural nasal spray developed for sinus headaches, cluster headaches and migraine headaches. Sinol prevents allergy triggers and relieves sinus pressure quickly and effectively. Is the future bright for Sinol? Vincent Schuman, President of Challenge Products and exclusive distributor of Sinol said, “The future is unlimited. Sinol is the only nasal headache spray in the analgesic category. With the active ingredient Capsaicin approved by the FDA for over-the-counter migraine headache relief, I’d say we have a very bright future.”

Consumers can expect to see SINOL in mass-market drug and super centers everywhere by the end of 2007. It is simply the most effective over-the-counter allergy treatment available and is unmatched as a migraine, cluster, and tension headache solution.

For more information, visit stgadv.com

New Pain Therapeutics Summit 2007 Announced

Arrowhead Conferences, a wing of Arrowhead Publishers, has announced their upcoming Pain Therapeutics Summit 2007, to take place in Jersey City, New Jersey on October 25th and 26th, 2007.

About one and a half billion people suffer from moderate to severe chronic pain worldwide and approximately 50 million Americans suffer with pain. The value of the pharmaceutical market for pain relief reflects this seeming worldwide epidemic of pain, with the overall value estimated at over $25 billion. There is thus great unmet need in the pharmacological treatment of pain around the world.

Arrowhead Conferences' Pain Therapeutics Summit 2007 brings together leaders from the pharmaceutical community to discuss new avenues of research in the field of pain therapeutics and the latest advances in the field.

At this conference, hear from experts in the field regarding new targets for pain relief in the areas of neuropathic pain, nociceptive pain, migraine pain, cancer pain, chronic pain and inflammatory conditions. Moreover, special consideration will be given to the roles that drug delivery and devices will play in the future management of pain.

Key themes of this conference will include: New drug discovery and targets in the area of pain management, Focus on clinical trials and regulatory issues facing developers of new pain medications, Specialty Pharma drug development activities in pain management, Licensing and investment issues revolving around the pain therapeutics market, Developments in the race to market abuse-resistant opioids, and Drug delivery technologies and their application to the field of pain management.

Therapeutic areas covered at this conference will include: neuropathic pain, migraine relief, chronic pain, nociceptive pain (eg. osteoarthritis, cancer pain).

Drug classes covered in this conference will include cannabinoids, triptans, anticonvulsants, opioids and analgesics.

For more information, visit arrowheadpublishers.com